These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26577754)

  • 21. Pharmacokinetics of the etonogestrel contraceptive implant in obese women.
    Mornar S; Chan LN; Mistretta S; Neustadt A; Martins S; Gilliam M
    Am J Obstet Gynecol; 2012 Aug; 207(2):110.e1-6. PubMed ID: 22717269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
    Duijkers I; Klipping C; Heger-Mahn D; Fayad GN; Frenkl TL; Cruz SM; Korver T
    Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):245-254. PubMed ID: 30203681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subdermal contraceptive implants.
    Peralta O; Diaz S; Croxatto H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
    Modesto W; Dal Ava N; Monteiro I; Bahamondes L
    Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability of ENG-releasing subdermal implants among postpartum Brazilian young women during the COVID-19 pandemic.
    Barbieri MM; Herculano TB; Dantas Silva A; Bahamondes L; Juliato CRT; Surita FG
    Int J Gynaecol Obstet; 2021 Jul; 154(1):106-112. PubMed ID: 33656758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
    Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
    Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
    Lazorwitz A; Sheeder J; Teal S
    Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism.
    Floyd JL; Beasley AD; Swaim LS; Turrentine MA; Nijjar JB
    Obstet Gynecol; 2020 Jun; 135(6):1275-1280. PubMed ID: 32459418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
    Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
    Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
    Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
    Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial.
    Brito MB; Ferriani RA; Meijers JC; Garcia AA; Quintana SM; Silva de Sá MF; Vieira CS
    Thromb Res; 2012 Sep; 130(3):355-60. PubMed ID: 22542366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
    Margatho D; Carvalho NM; Bahamondes L
    Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
    [No Abstract]   [Full Text] [Related]  

  • 34. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports.
    Ciangura C; Corigliano N; Basdevant A; Mouly S; Declèves X; Touraine P; Lloret-Linares C
    Contraception; 2011 Dec; 84(6):649-51. PubMed ID: 22078197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users.
    Lazorwitz A; Dindinger E; Harrison M; Aquilante CL; Sheeder J; Teal S
    Contraception; 2020 Sep; 102(3):180-185. PubMed ID: 32407811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population.
    Di Carlo C; Guida M; De Rosa N; Sansone A; Gargano V; Cagnacci A; Nappi C
    Gynecol Endocrinol; 2015 Jun; 31(6):491-4. PubMed ID: 26213863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period.
    Villas-Boas J; Vilodre LC; Malerba H; Pontremoli Salcedo M; Foresti Jiménez M; El Beitune P
    Eur J Obstet Gynecol Reprod Biol; 2016 Jul; 202():51-4. PubMed ID: 27164485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
    Short M; Dallay D; Omokanye S; Stauch K; Inki P
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
    Wenzl R; van Beek A; Schnabel P; Huber J
    Contraception; 1998 Nov; 58(5):283-8. PubMed ID: 9883383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.